Application model for cardiovascular basis and drug screening and construction method
By constructing a 3D microvascular model and a high hydrostatic intervention system, the problem of insufficient structure and interaction of two-dimensional cell models in hypertension research is solved, accurate research on vascular biology and drug screening are achieved, and new diagnosis and Treatment ideas.
Patent Information
- Application Number
- CN202410978781.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing two-dimensional cell model has structural defects in the study of hypertension pathogenesis, and cannot accurately simulate the interaction between three-dimensional structure and cells, resulting in inaccuracy of the research results and limitations of drug screening, and is out of touch with basic research.
A 3D model of microvascular perfusion can be constructed in vitro, through spatial co-culture of vascular endothelial cells, vascular smooth muscle cells and stromal fibroblasts, simulates the perfusion network of the cardiovascular system, and combines a high hydrostatic pressure intervention system to simulate the real hypertension physiology and the efficacy of the drug is verified through data collection and analysis.
Accurate research on vascular biology and hypertension pathological mechanisms has been achieved, providing an effective drug screening platform, able to simulate the real hypertension physiological environment, help understand the mechanism of vascular disease occurrence and provide new ideas for diagnosis and treatment.
Smart Images

Figure CN118909918A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of basic medical research and the field of biological detection drug technology, and specifically relates to an application model and a construction method for cardiovascular basic and drug screening. Background Art
[0002] Hypertension is a chronic non-communicable disease worldwide. Although much progress has been made in the study of the pathogenesis of hypertension, there are still some defects and shortcomings, such as: the joint action of multiple factors and multiple mechanisms makes it difficult to fully reveal its pathogenesis, there is a lack of effective therapeutic targets, and most importantly, the disconnection between clinical and basic research. The animal models and cell biology models currently used in the study of the pathogenesis of hypertension are significantly different from clinical practice.
[0003] The following research methods are commonly used in the study of the mechanism of hypertension: cell experiments, animal experiments, molecular biology techniques, imaging techniques, etc. Although molecular biology techniques can efficiently study the expression and function of genes and proteins related to hypertension, their results need to be further verified in cell and animal experiments. The main reason for the difference between the results of cell experiments and animal experiments and the situation of human hypertension is the imperfection of cell models and intervention methods. At present, most cell models use two-dimensional cell models, and the intervention methods are mostly chemical reagents, small molecule drugs, various gene vectors, etc. The disadvantages of two-dimensional cell models may include the following aspects: 1. Lack of three-dimensional structure: 2D models cannot simulate the three-dimensional structure and spatial relationship between cells in real tissues, which may lead to limitations in the understanding of cell behavior and function. 2. Lack of cell interaction: In 2D culture, cells lack interactions with adjacent cells and matrix, which are crucial in maintaining cell position, function and signaling pathways. 3. Loss of phenotype: Purified primary cell populations may lose their original phenotypes in 2D culture, which affects the physiological relevance of the research results. 4. Differences in functions and signaling pathways: Due to the lack of cell-to-cell interactions, cell functions and signaling pathways in 2D models may differ from those in vivo, which may lead to inaccurate research results. 5. Limitations of drug screening: The application of 2D models in preclinical drug screening is limited because they often fail to construct effective tumor biology models, resulting in insufficient predictive power of drug responses. 6. Lack of physiological function: Compared with 3D models, 2D models usually lack structural organization and physiological functions similar to native organs, which affects their application in studying developmental processes, tissue homeostasis, etc. 7. Genomic stability issues: In some cases, long-term cultured 2D cell models may experience genomic instability, which may affect the accuracy and reproducibility of experimental results. Summary of the invention
[0004] The purpose of the present invention is to provide an application model and construction method for cardiovascular basic and drug screening, aiming to solve the problems raised by the background technology.
[0005] To achieve the above objectives, the present invention provides the following technical solutions: an application model for cardiovascular basics and drug screening, including an in vitro perfusable microvascular 3D model for high hydrostatic pressure intervention, wherein the microvascular 3D model is constructed by spatially controlled co-culture of vascular endothelial cells, vascular smooth muscle cells and matrix fibroblasts to achieve a perfusable network simulating the cardiovascular system for tissue engineering and vascular function modeling.
[0006] As a preferred solution of the present invention, the in vitro vascular model can help researchers study the physiological and pathological processes of blood vessels without conducting animal experiments. By detecting the spatial conformation of vascular endothelial cells, vascular smooth muscle cells and matrix fibroblasts, the role of single-cell systems in perfusable vascular systems can be examined, which can be used to understand vascular biology, disease mechanisms and drug screening.
[0007] As a preferred solution of the present invention, the microvascular 3D model is a biodynamic model that can accurately reproduce the response of endothelial cells and smooth muscle cells under hemodynamics, such as physiological shear stress, which is essential for growing perfusable functional 3D vascular networks and studying the pathological mechanisms and prevention and treatment of primary hypertension and secondary hypertension.
[0008] As a preferred solution of the present invention, the microvascular 3D model is a microfluidic platform that can simulate the natural cellular program during normal development and angiogenesis to form complete 3D microvessels with the characteristic morphology and biochemical markers of in vivo blood vessels. The established microvascular model has strong barrier function and long-term stability, and can respond realistically to flow-induced mechanical stimulation, such as cytoskeleton rearrangement and extracellular matrix cross-linking.
[0009] A method for constructing a microvascular 3D model, according to any one of the application models described above, the method for constructing a microvascular 3D model comprises the following steps:
[0010] (1) Isolate and extract rat aortic endothelial cells, smooth muscle cells and vascular outer layer fibroblasts;
[0011] (2) endothelial cells and fibroblasts were mixed with collagen and added to the inner and outer layers of the artery mold, respectively, and cultured at 37°C for 1 hour to allow the gel to solidify;
[0012] (3) Smooth muscle cells were mixed with collagen, added to the middle layer of the artery mold, and cultured at 37°C for 1 hour to allow the gel to solidify;
[0013] (4) Add culture medium to the artery mold and continue incubating for 48 hours to obtain a microvascular 3D model.
[0014] As a preferred solution of the present invention, the high hydrostatic pressure intervention includes a high hydrostatic pressure connecting device, a pressurizing device, a pressure catheter and a data acquisition system, wherein the high hydrostatic pressure connecting device is connected to the pressurizing device, one end of the pressure catheter is inserted into the microvascular 3D model, and the other end is connected to the data acquisition system. High hydrostatic pressure is applied to the microvascular 3D model by adjusting the pressurizing device, and the pressure catheter monitors the changes in hydrostatic pressure in real time, and transmits the pressure data to the data acquisition system for recording and analysis.
[0015] As a preferred solution of the present invention, the model detects structural changes of the microvascular 3D model, including changes in vascular wall collagen and cells, through confocal microscopy three-dimensional imaging technology; and can also detect changes in vascular wall tension and hardness through vascular tension measurement technology.
[0016] As a preferred solution of the present invention, the microvascular 3D model is used to study various biological processes of angiogenesis, vascular lesions, and tumor growth, as well as changes in the physiological and pathological environment of blood vessels when pressure conditions change. It can also be used as a platform for drug screening and toxicity testing.
[0017] As a preferred embodiment of the present invention, the model is used to detect drug sensitivity, and the drug includes an ingredient that can reduce or downregulate the activity of a biomarker; the active ingredient is preferably selected from an inhibitor, a neutralizing antibody or a polypeptide of the biomarker; the drug may also include a pharmaceutically acceptable excipient; the hypertension drug includes a drug for preventing and treating primary hypertension and secondary hypertension.
[0018] As a preferred solution of the present invention, the model uses computer simulation to take the effect of the drug under hydrostatic pressure intervention as an input variable to evaluate the efficacy of the drug, optimize the dosing regimen, and provide new ideas and methods for the prevention and treatment of cardiovascular diseases such as hypertension.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] 1) Construction of 3D vascular model: The system uses matrix gel model and co-culture technology of primary vascular endothelial cells, vascular smooth muscle cells and fibroblasts to construct a highly realistic 3D vascular model;
[0021] 2) High hydrostatic pressure intervention: high hydrostatic pressure is applied through the control system to intervene in the 3D vascular model to simulate the real physiological environment of hypertension;
[0022] 3) Data collection and analysis: The system can collect and record various parameters during the intervention process, such as pressure, vascular wall deformation, etc., in real time, and perform data analysis and processing;
[0023] 4) Result visualization: The system can display the intervention results in a graphical way, which is convenient for researchers to observe and analyze. The system can simulate the pathophysiological environment of real primary hypertension and pressure-load secondary hypertension. By constructing a 3D vascular model high hydrostatic pressure intervention system and verifying its function, it has a wide range of application prospects in cardiovascular disease research, helping researchers to better understand the pathogenesis of vascular biology and cardiovascular disease, and provide new ideas and methods for the diagnosis and treatment of diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0025] Figure 1 A is the horizontal axis diagram of the 3D vascular model constructed by primary vascular cells;
[0026] Figure 1 B is the longitudinal axis image of the 3D vascular model constructed by primary vascular cells;
[0027] Figure 2 This is the aSMA staining image of the vascular model;
[0028] Figure 3 Pressure regulation and monitoring diagrams of 3D vascular models for hydrostatic intervention at different pressures;
[0029] Figure 4 This is a schematic diagram of the 3D vascular high hydrostatic pressure intervention system. DETAILED DESCRIPTION
[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0031] Example 1
[0032] See also Figure 1-4The present invention provides the following technical solutions: an application model for cardiovascular basics and drug screening, including an in vitro perfusable microvascular 3D model for high hydrostatic pressure intervention, the microvascular 3D model is constructed by spatially controlled co-culture of endothelial cells with matrix fibroblasts and pericytes, to achieve a perfusable network simulating the cardiovascular system, which is used for tissue engineering and vascular function modeling.
[0033] In vitro vascular models can help researchers study the physiological and pathological processes of blood vessels without conducting animal experiments. By detecting the spatial conformation of endothelial cells, vascular smooth muscle cells, and stromal fibroblasts, the role of single-cell systems in perfused vasculature can be examined, which can be used to understand vascular biology, disease mechanisms, and drug screening.
[0034] The microvascular 3D model is a biodynamic model that can accurately reproduce the response of endothelial cells and smooth muscle cells under hemodynamics, such as physiological shear stress, and is essential for growing perfusable functional 3D vascular networks and studying the pathological mechanisms and prevention and treatment of primary hypertension and secondary hypertension, respectively.
[0035] The microvascular 3D model is a microfluidic platform that can simulate the natural cellular program during normal development and angiogenesis, forming complete 3D microvessels with the characteristic morphology and biochemical markers of in vivo blood vessels. The established microvascular model has strong barrier function and long-term stability, and can respond realistically to flow-induced mechanical stimulation, such as cytoskeleton rearrangement and extracellular matrix cross-linking.
[0036] A method for constructing a microvascular 3D model, according to any one of the application models described above, the method for constructing a microvascular 3D model comprises the following steps:
[0037] (1) Isolation and extraction of rat aortic endothelial cells, smooth muscle cells and fibroblasts;
[0038] (2) endothelial cells and fibroblasts were mixed with collagen and added to the inner and outer layers of the artery mold, respectively, and cultured at 37°C for 1 hour to allow the gel to solidify;
[0039] (3) Smooth muscle cells were mixed with collagen, added to the middle layer of the artery mold, and cultured at 37°C for 1 hour to allow the gel to solidify;
[0040] (4) Add culture medium to the artery mold and continue incubating for 48 hours to obtain a microvascular 3D model.
[0041] The high hydrostatic pressure intervention includes a high hydrostatic pressure connecting device, a pressurizing device, a pressure catheter and a data acquisition system, wherein the high hydrostatic pressure connecting device is connected to the pressurizing device, one end of the pressure catheter is inserted into the microvascular 3D model, and the other end is connected to the data acquisition system. High hydrostatic pressure is applied to the microvascular 3D model by adjusting the pressurizing device, and the pressure catheter monitors the changes in hydrostatic pressure in real time, and transmits the pressure data to the data acquisition system for recording and analysis.
[0042] The model uses confocal microscopy three-dimensional imaging technology to detect structural changes in the microvascular 3D model, including changes in the amount of vascular wall collagen secretion, routing, cross-linking, and cell proliferation, migration, and differentiation; and can also use vascular tension measurement technology to detect changes in vascular wall tension and hardness.
[0043] The microvascular 3D model is used to study various biological processes of angiogenesis, vascular lesions, tumor growth, and changes in the physiological and pathological environment of blood vessels when pressure conditions change. It can also be used as a platform for drug screening and toxicity testing.
[0044] The model is used to detect drug sensitivity, and the drug includes ingredients that can reduce or downregulate the activity of biomarkers; the active ingredient is preferably selected from inhibitors, neutralizing antibodies or polypeptides of the biomarkers; the drug may also include pharmaceutically acceptable excipients; the hypertension drug includes drugs for preventing and treating primary hypertension and secondary hypertension.
[0045] The model uses computer simulation to take the effect of drugs under hydrostatic pressure intervention as input variables, evaluates the efficacy of drugs, optimizes dosing regimens, and provides new ideas and methods for the prevention and treatment of cardiovascular diseases such as hypertension.
[0046] Specifically,
[0047] 1. Constructing 3D model of blood vessels:
[0048] A. Extract aortic endothelial cells, smooth muscle cells and fibroblasts from SD rats and SHR rats;
[0049] ①. Kill the rat with CO2, and immerse the whole rat in 75% ethanol for about 1 minute for disinfection. Under sterile conditions, cut the chest cavity layer by layer, separate and remove the aorta, and place it in a culture dish containing D-Hanks' solution.
[0050] ②. Use ophthalmic scissors and forceps to remove as much fat and fibrous tissue as possible from the adventitia of the blood vessels. Then, rinse the outer surface of the blood vessels and the blood clots in the blood vessel cavity several times with D-Hanks' solution containing antibiotics, and then place them in another sterile culture dish.
[0051] ③. Use ophthalmic scissors to cut the blood vessels longitudinally and spread them flat in a culture dish. Use microsurgical forceps to peel off the endothelial layer, middle layer and outer layer of the blood vessels respectively, and use a very sharp scalpel to cut them into 1mm3 arterial grafts, and then plant them in culture dishes respectively.
[0052] ④. Place the intimal surface of the endothelial artery graft in contact with the bottom of the bottle, with a planting density of about 1 piece / cm2. Place in an incubator and let stand for 2 hours (dry adherence). Then, add 0.5 ml of endothelial cell complete culture medium containing 25% fetal bovine serum. The amount of liquid should be enough to slightly cover the intimal surface of the artery graft, but not to make the graft float. After 24 hours, replace the culture medium and add 2-3 ml of culture medium.
[0053] ⑤. After about 72 hours, when endothelial cells are observed to have fully grown, the arterial explants are transferred to a new cell culture dish and the culture medium is changed once. The culture is continued for 8-10 days until the cells fuse into a single layer and can be passaged.
[0054] ⑥. Attach the arterial middle layer graft to the bottom of the culture dish, using the same method as ④⑤, and culture with vascular smooth muscle cell complete culture medium. The obtained cells are smooth muscle cells.
[0055] ⑦. Attach the outer artery block to the bottom of the culture dish. Use the same method as ④⑤ and culture it with complete fibroblast culture medium to eliminate endothelial cells and smooth muscle cells. The resulting cells are fibroblasts.
[0056] B, Co-culture of matrix gel and cells to construct 3D blood vessels;
[0057] ①. Trypsinize and resuspend cells, and count endothelial cells, vascular smooth muscle cells, and fibroblasts;
[0058] ②. Each arterial ring requires 60,000 endothelial cells and 1 mg collagen, with a final total volume of 100 u l (1 mg / ml), and the mixture is added to the inner layer of the arterial mold. 50,000 fibroblasts and 1 mg collagen, with a final total volume of 100 u l (1 mg / ml), are added to the outer layer of the arterial mold.
[0059] ③. Culture in a 37℃ CO2 cell culture incubator for 1 hour to allow the gel to solidify.
[0060] ④. Add 120,000 smooth muscle cells and 2 mg collagen, with a final total volume of 200 μl (1 mg / ml), to the middle layer of the artery mold.
[0061] ⑤. After incubating in a 37℃ CO2 cell culture incubator for 1 hour to allow the gel to solidify, add culture medium to each mold and continue incubating for 48 hours.
[0062] The 3D vascular ring was successfully prepared through the above steps.
[0063] 2. Establishment of high hydrostatic pressure intervention device:
[0064] A. Construct high hydrostatic pressure connection and pressurization device;
[0065] The artery mold was placed in a hydrostatic intervention device connected to a pressurized syringe.
[0066] B. Connect the Millar pressure catheter and PowerLab data acquisition system to monitor the hydrostatic pressure.
[0067] The hydrostatic pressure intervention device measurement catheter is connected to the Millar catheter, which is connected to the PowerLab system. The Millar catheter sensor is immersed in the culture medium of the vascular mold. Labchart8 software records the pressure data when the syringe is pressurized.
[0068] 3. Detection of vascular model structure and function:
[0069] A. Confocal microscope three-dimensionally photographs 3D blood vessel model samples to clarify the changes in collagen in the blood vessel wall;
[0070] Collagen can spontaneously fluoresce, and confocal microscopy can be used to reconstruct the three-dimensional structure of 3D vascular rings and clarify the arrangement of extracellular matrix collagen.
[0071] B. Immunofluorescence staining of floating tissue blocks to clarify changes in vascular wall cells;
[0072] Immunofluorescence staining of floating tissue blocks. The experiment included four groups: 3D vascular rings from SD with and without high hydrostatic pressure intervention, and 3D vascular rings from SHR with and without high hydrostatic pressure intervention. The specific staining steps are as follows:
[0073] ① Blocking: Cover the sample completely with 5% blank goat serum. The three-dimensional vascular tissue block needs to be placed in a wet box and incubated at 37°C for 2 hours;
[0074] ② Primary antibody incubation: remove the blocking solution, add the primary antibody working solution (a-SMC antibody) prepared with TBS buffer directly on the sample, the sample must be completely covered, placed in a wet box, and incubated at 4°C for 48 hours;
[0075] ③ Washing: remove the primary antibody and wash three times with 1x TBS at room temperature (the first two washes were 30 seconds, and the final wash was 10 minutes);
[0076] ④ Secondary antibody incubation: prepare 1 mL of secondary antibody dilution solution for each sample (the diluent consists of 1x TBS with 0.3% Triton X-100 and 1% normal serum), and incubate at room temperature with shaking in the dark for 2 hours;
[0077] ⑤ Washing: Remove the secondary antibody and wash three times with 1x TBS at room temperature (the first two washes were 30 seconds, and the final wash was 10 minutes);
[0078] ⑥DAP I staining: add DAP I (1-0.1 μg / ml) and incubate at room temperature for 30 minutes in the dark;
[0079] ⑦ Washing: Remove DAP I and wash three times with 1x TBS at room temperature (the first two washes were 30 seconds, and the last wash was 15 minutes);
[0080] ⑧3D vascular tissue blocks were placed on glass slides and stored in a light-proof humidified box at 4°C;
[0081] ⑨ Confocal microscopy was used to perform three-dimensional reconstruction imaging of 3D vascular tissue blocks.
[0082] C. Vascular tension measuring instrument measures changes in vascular wall tension and hardness;
[0083] The 620M multi-channel vascular tension measuring instrument measures the changes in wall tension and stiffness of 3D blood vessels, SD rats, and SHR rats’ thoracic aorta segments:
[0084] ①.Prepare solution:
[0085] HT buffer: NaCl 137mmol / L; KCl 4mmol / L; CaCl 22mmol / L; MgCl 2 2mmol / L; Glucose 5.6mmol / L; HEPES 5mmol / L, neutralized to pH 7.4;
[0086] KC I HT buffer: NaC l 15.7mmo l / L; KC I 124mmo l / L; CaC l 21.0mmo l / L; MgC l 2 2.0mmo l / L; glucose 5.6mmo l / L; HEPES 10mmo l / L, neutralized to pH 7.4.
[0087] ②. Move the 3D blood vessel to the complete culture medium in the water bath, cut a 2-3 cm thin steel wire (smaller than the diameter of the water bath for easy operation), gently clamp the blood vessel wall with micro forceps, carefully insert the thin steel wire into the blood vessel, and then use a screwdriver to fix the steel wire on both sides of the screw. Use the same method to insert another steel wire and fix the blood vessel in the water bath.
[0088] ③. Open the Chart software, turn on the oxygen and temperature switches, and balance at 37°C with oxygen supply for 30 minutes;
[0089] ④. When the basic tension is adjusted to balance the tension curve, adjust to zero. Then adjust the blood vessel diameter with a spiral micrometer, at a scale of 1 μm each time, at a frequency of 1 time / minute, until the blood vessel wall pressure is 13.3 kPa (100 mmHg). The value shown in X1 is the required inner diameter value under the basic tension condition of the blood vessel;
[0090] ⑤. After 20 minutes of equilibrium, stimulate with KPPS solution for 3 times in a row, with a 10-minute interval between each time;
[0091] ⑥. After 20 minutes of equilibration, stimulate with 10uM norepinephrine for 3 minutes, then add 1uM acetylcholine, and wash four times with equilibration solution after 2 minutes.
[0092] ⑦. The entire process of changes in vascular tension was recorded using LabChart 8 software.
[0093] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. An application model for cardiovascular basic and drug screening, characterized in that: The invention comprises an in vitro perfusable microvascular 3D model for high hydrostatic pressure intervention. The microvascular 3D model is constructed by spatially controlled co-culture of vascular endothelial cells, vascular smooth muscle cells and matrix fibroblasts to realize a perfusable network simulating the cardiovascular system for tissue engineering and vascular function modeling.
2. The application model for cardiovascular basic and drug screening according to claim 1, characterized in that: The in vitro vascular model can help researchers study the physiological and pathological processes of blood vessels without conducting animal experiments. By detecting the spatial conformation of endothelial cells, vascular smooth muscle cells, and stromal fibroblasts, the role of single-cell systems in perfused vascular systems can be examined, which can be used to understand vascular biology, disease mechanisms, and drug screening.
3. The application model for cardiovascular basic and drug screening according to claim 1, characterized in that: The microvascular 3D model is a biodynamic model that can accurately reproduce the response of endothelial cells and smooth muscle cells under hemodynamics, such as physiological shear stress, and is essential for growing perfusable functional 3D vascular networks and studying the pathological mechanisms and prevention and treatment of primary hypertension and secondary hypertension, respectively.
4. The application model for cardiovascular basic and drug screening according to claim 1, characterized in that: The microvascular 3D model is a microfluidic platform that can simulate the natural cellular program during normal development and angiogenesis to form complete 3D microvessels with the characteristic morphology and biochemical markers of in vivo blood vessels. The established microvascular model has strong barrier function and long-term stability, and can respond realistically to flow-induced mechanical stimulation, such as cytoskeleton rearrangement and extracellular matrix cross-linking.
5. A method for constructing a microvascular 3D model, according to the application model according to any one of claims 1 to 4, characterized in that: The method for constructing the microvascular 3D model comprises the following steps: (1) Isolation and extraction of rat aortic endothelial cells, smooth muscle cells and fibroblasts; (2) endothelial cells and fibroblasts were mixed with collagen, added to the endothelial layer and the outer cortex of the artery mold, respectively, and cultured at 37°C for 1 hour to allow the gel to solidify; (3) Smooth muscle cells were mixed with collagen, added to the middle layer of the artery mold, and cultured at 37°C for 1 hour to allow the gel to solidify; (4) Add culture medium to the artery mold and continue incubating for 48 hours to obtain a microvascular 3D model.
6. The application model for cardiovascular basic and drug screening according to any one of claims 1 to 4, characterized in that: The high hydrostatic pressure intervention includes a high hydrostatic pressure connecting device, a pressurizing device, a pressure catheter and a data acquisition system, wherein the high hydrostatic pressure connecting device is connected to the pressurizing device, one end of the pressure catheter is inserted into the microvascular 3D model, and the other end is connected to the data acquisition system. High hydrostatic pressure is applied to the microvascular 3D model by adjusting the pressurizing device, and the pressure catheter monitors the changes in hydrostatic pressure in real time, and transmits the pressure data to the data acquisition system for recording and analysis.
7. The application model for cardiovascular basic and drug screening according to any one of claims 1 to 4, characterized in that: The model detects structural changes of the microvascular 3D model, including changes in vascular wall collagen and cells, through confocal microscope three-dimensional imaging technology; and can also detect changes in vascular wall tension and hardness through vascular tension measurement technology.
8. The application model for cardiovascular basic and drug screening according to any one of claims 1 to 4, characterized in that: The microvascular 3D model is used to study various biological processes of angiogenesis, vascular lesions, tumor growth, and changes in the physiological and pathological environment of blood vessels when pressure conditions change. It can also be used as a platform for drug screening and toxicity testing.
9. The application model for cardiovascular basic and drug screening according to claim 8, characterized in that: The model is used to detect drug sensitivity, and the drug includes ingredients that can reduce or downregulate the activity of biomarkers; the active ingredient is preferably selected from inhibitors, neutralizing antibodies or polypeptides of the biomarkers; the drug may also include pharmaceutically acceptable excipients; the hypertension drug includes drugs for preventing and treating primary hypertension and secondary hypertension.
10. The application model for cardiovascular basic and drug screening according to claim 9, characterized in that: The model uses computer simulation to take the effect of drugs under hydrostatic pressure intervention as input variables, evaluates the efficacy of drugs, optimizes dosing regimens, and provides new ideas and methods for the prevention and treatment of cardiovascular diseases such as hypertension.
